Beckley Psychech, a British biotechnology company in clinical stage

Beckley Psychech was founded in 2019, Headquartered in the UK Oxford Beckley, Beckley Psychech is a clinical Biotechnology Company , dedicated to exploring the therapeutic potential of psychedelic substances.

The article originates from the home of American stocks | encyclopedia of American stocks | account opening and investment of American and Hong Kong stocks- https://www.mg21.com/beckleypsytech.html

Beckley Psychech Encyclopedia of US Stocks

Beckley Psychech was hatched from the Beckley Foundation. Based on 20 years of scientific research, the company combines the world's leading hallucinogenic science, clinical drug development expertise and pioneering methods in the use of digital tools to optimize the treatment effect of patients, thoroughly reform the treatment method, and reduce the burden of these diseases on patients and society. The article originates from the home of American stocks | encyclopedia of American stocks | account opening and investment of American and Hong Kong stocks- https://www.mg21.com/beckleypsytech.html

Amanda has been committed to the scientific exploration of psychedelic drugs for more than 50 years, and believes that modern science can be used to understand, verify and optimize the therapeutic potential of psychedelic drugs. In 1998, Amanda established (and continued to operate) the Beckley Foundation, a non-profit non-governmental organization focusing on evidence-based drug policy reform and scientific research on hallucinogenic drugs. The article originates from the home of American stocks | encyclopedia of American stocks | account opening and investment of American and Hong Kong stocks- https://www.mg21.com/beckleypsytech.html

In the past 20 years, the Beckley Foundation has become a world famous pioneer in hallucinogenic research. Amanda is known as "the driving force behind the renaissance of hallucinogenic science", listed in the "Bravest Men and Women in the History of Science" of the Guardian, and personally co authored with more than 50 peer reviewed scientific publications, many of which have groundbreaking achievements. The article originates from the home of American stocks | encyclopedia of American stocks | account opening and investment of American and Hong Kong stocks- https://www.mg21.com/beckleypsytech.html

Beckley Psychech was established to develop safe and effective psychedelic drugs for patients in need based on the work of the Foundation, and integrate these treatments into mainstream medical practice. Beckley Psychech has established a close strategic partnership with the Beckley Foundation. In addition to its own channels, it will also provide financial and technical support to develop the foundation's most promising research. The company is committed to improving the lives of patients in need, and will donate part of future income to fund the non-profit work of the foundation. The article originates from the home of American stocks | encyclopedia of American stocks | account opening and investment of American and Hong Kong stocks- https://www.mg21.com/beckleypsytech.html

Beckley Psychech is a psychedelic drug company dedicated to exploring the therapeutic potential of psychedelic substances (such as nudicopsin and other compounds) in mental health treatment. Beckley Psychech envisions integrating clinically proven psychedelic drugs into contemporary medical practice to help individuals cope with depression and other serious debilitating neuropsychiatric diseases characterized by a large number of unmet needs. The article originates from the home of American stocks | encyclopedia of American stocks | account opening and investment of American and Hong Kong stocks- https://www.mg21.com/beckleypsytech.html

Thanks to Beckley Psychech's unique inheritance and science driven approach, the company can cooperate with world-class experts and establish a global network, including world-class doctors, scientists and thought leaders, to assist Beckley Psychech in providing innovative solutions in areas with high unmet needs. The article originates from the home of American stocks | encyclopedia of American stocks | account opening and investment of American and Hong Kong stocks- https://www.mg21.com/beckleypsytech.html

Beckley Psychech product line

Beckley Psychech is developing a series of differentiated psychedelic products for mental and nervous system diseases: The article originates from the home of American stocks | encyclopedia of American stocks | account opening and investment of American and Hong Kong stocks- https://www.mg21.com/beckleypsytech.html

The article originates from the home of American stocks | encyclopedia of American stocks | account opening and investment of American and Hong Kong stocks- https://www.mg21.com/beckleypsytech.html

• Depression : Currently available drugs are not effective for all patients with depression. Treatment resistant depression (TRD) is a term used when two or more different antidepressants are ineffective, which can occur in as many as one third of patients with major depression (MDD). TRD brings a huge burden to the health care system. Beckley Psychech's psychological support method aims to achieve clinically significant improvement with less time and resources by using highly effective and short-term psychedelic drugs.
• Alcohol Use Disorder : Alcohol use disorder (AUD) is a medical condition characterized by inability to stop or control alcohol use when facing adverse social, occupational or health consequences. It includes what some people call alcohol abuse, alcohol dependence, alcohol addiction, and "alcoholism" in oral language. AUD is a common and fatal condition. According to the Center for Disease Control and Prevention (CDC), more than 140000 people die of AUD in the United States every year. Some patients with alcohol use disorders who wish to quit drinking or reduce alcohol consumption fail to achieve their treatment goals through the currently approved treatment options. There are still huge unmet medical needs for these patients, which also provides opportunities for new treatments.

Beckley Psychech Financing Encyclopedia

In June 2020, Beckley Psychech completed a round A financing of 12 million pounds, co invested by JamJar Investments, Oryx Ventures, Berti Investments, Bicycle Day Ventures, Mediqventures, etc. The article originates from the home of American stocks | encyclopedia of American stocks | account opening and investment of American and Hong Kong stocks- https://www.mg21.com/beckleypsytech.html

In December 2020, Beckley Psychech raised 14 million pounds of venture capital, which was jointly participated by Redbus Ventures, Noetic Fund, Bicycle Day Ventures, Bail Capital, etc.

In August 2021, Beckley Psychech completed the round B financing of 58 million pounds FJ Labs , Adaptation Capital Management, What If Ventures, Prime Movers Lab, The CATALYTIC IMPACT FOUNDATION (CIF) and other joint investments.

In January 2024, Beckley Psychech won the exclusive secondary market investment of $10 million from ATAI Life Sciences.

In January 2024, Beckley Psychech acquired an exclusive $40 million stake in ATAI Life Sciences.

Beckley Psychech US equity investment

Unlisted company ， Company official website , wait for Beckley Psychech IPO Listing.